Synlogic stock.

What is Synlogic's consensus rating and price target? According to the issued ratings of 2 analysts in the last year, the consensus rating for Synlogic stock is Buy based on the current 2 buy ratings for SYBX. The average twelve-month price prediction for Synlogic is $82.50 with a high price target of $90.00 and a low price target of $75.00.Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October financing of $19.6 million (net), and an additional $2.5 million earned from the Roche research collaboration milestone announced in November.Support, Risk & Stop-loss for Synlogic Inc stock. On the downside, the stock finds support just below today's level from accumulated volume at $2.14 and $2.07. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level.Fourth Quarter 2022 Financial Results. As of December 31, 2022, Synlogic had cash, cash equivalents, and short-term marketable securities of $77.6 million. Revenue was $0.1 million for the three ...Starting us off today is Twist Biosciences. In brief, Twist is a leading name in the synthetic biology industry today. The company’s core work revolves around its proprietary DNA synthesis ...

Chardan Raises Price Target on Synlogic to $6 From $5.50 Reflecting Lower Cash Burns Due to Recent Downsizing, Keeps Buy Rating. Jun. 06. MT. SVB Securities Cuts Synlogic's Price Target to $4 From $8, Maintains Outperform Rating. May. 12. MT. HC Wainwright Lowers Synlogic's Price Target to $5 From $7, Buy Rating Kept.If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...

Synlogic Inc stock performance at a glance. Check Synlogic Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and …

Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.CAMBRIDGE, Mass., Sept. 20, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced positive data from clinical studies evaluating both SYNB1618 and SYNB1934, investigational Synthetic Biotic™ medicines for the treatment …Kelly’s belief in synthetic biology is unflagging, and his support has continued even as Synlogic’s stock price has slumped, erasing about three quarters of Ginkgo’s investment on paper.Mar 29, 2023 · CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ... Synlogic has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off last year's report dates. Learn more on SYBX's earnings history.

2.46. +0.16. +6.96%. Get Synlogic Inc (SYBX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

SYBX one year forecast. Synlogic stock monthly and weekly forecasts. Skip to content. FORECST.COM 2023 – 2026 Stock Market Forecast SYBX stock forecast for 2023 – 2027. Last updated: November 30, 2023. Are you interested in Synlogic, Inc. stocks prediction?

Synthetic biology is an entirely new strategy in drug development, affording us the opportunity to design selective and potent living medicines to treat disease. With a team of experienced scientists and executives at the helm, Synlogic is forging new ground to advance this approach and design novel therapeutics to treat unmet medical needs.CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...Stock Information. Stock Quote & Chart; Analyst Coverage; Corporate Governance. Governance Highlights; Management Team; Board of Directors; Committee …CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that it will implement a 1-for-15 Reverse Stock Split of its common stock …Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 19.23% and 80.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?Synlogic (NASDAQ:SYBX) is undoubtedly a potential 10X investment, judging by its numbers alone. Shares of SYBX stock trade at only 53 cents per share, while its target stock price is $7.17 .Aoife Brennan, Synlogic CEO. Synlogic “We have been working with Ginkgo for over two years now,” said Aoife Brennan, Synlogic CEO. “We initially started with a pilot project that went so ...

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Michael Jensen as Chief Financial Officer. Mr. …Synlogic (SYBX) Presents At Jefferies 2017 London Healthcare Conference - Slideshow. SA Transcripts Fri, Nov. 17, 2017 1 Comment. All earnings call transcripts on Synlogic, Inc. (SYBX) stock. Read ...Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 ... Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in …Synlogic Inc stocks price quote with latest real-time prices, charts, financials, latest news, ... Do the numbers hold clues to what lies ahead for the stock? SYBX: 0.8376 (-3.60%) ROIV: 5.14 (-2.10%) Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks PR Newswire - Thu Aug 11, 6:05AM CDTSynlogic enacted this reverse stock split to boost the price of its shares and avoid delisting. The company’s stock previously closed out trading at just 28 cents. That’s below the $1 minimum ...

Founded Date 2014. Founders Alison Silva, Ankit Mahadevia, Dean Falb, Jim Collins, Timothy K. Lu. Operating Status Closed. Last Funding Type Post-IPO Equity. Legal Name Synlogic, Inc. Stock Symbol NASDAQ:SYBX. Company Type For Profit. Contact Email [email protected]. Phone Number (617)401-9975.

Dec 1, 2023 · Earnings Flash (SYBX) SYNLOGIC Posts Q3 Revenue $393,000. Nov. 09. MT. Synlogic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 09. CI. Synlogic, Inc. Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration. Nov. 07. CI. The upgrade of Synlogic, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.Stock Information. Stock Quote & Chart; Analyst Coverage; Corporate Governance. Governance Highlights; Management Team; Board of Directors; Committee …CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that it will implement a 1-for-15 Reverse Stock Split of its common stock (Reverse Stock Split), effective at 5:00 p.m. Eastern Time on Wednesday ...Third Quarter 202 1 Financial Results. As of September 30, 2021, Synlogic had cash, cash equivalents, and short-term investments of $150 .1 million. For the three months ended September 30, 2021 ...$-12.72 Market Cap $18.29 M Shares Outstanding 9.19 M Public Float 4.54 M Yield SYBX is not currently paying a regular dividend. Latest Dividend N/A Ex-Dividend Date N/A Short …Synlogic, Inc. CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S ...Third Quarter 202 1 Financial Results. As of September 30, 2021, Synlogic had cash, cash equivalents, and short-term investments of $150 .1 million. For the three months ended September 30, 2021 ...CAMBRIDGE, Mass., Dec. 14, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 has advanced into the combination therapy stage of the ongoing Phase 1 trial.SYNB1891 is an investigational drug for the intra-tumoral treatment …Nov 30, 2023 · View Synlogic, Inc SYBX investment & stock information. Get the latest Synlogic, Inc SYBX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.

Grading Synlogic Inc Stock. Before you choose to buy, sell or hold Synlogic Inc stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement.

24.65%. Get the latest Synlogic Inc (SYBX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Over the past 3 months, 6 analysts have published their opinion on Synlogic (NASDAQ:SYBX) stock. These analysts are typically employed by large Wa...In discussing Synlogic (NASDAQ: SYBX) stock, let’s begin with the upside because it’s substantial. SYBX shares carry an average target price of $7.17 yet trade for $0.65.Jun 30, 2023 · Second Quarter 2023 Financial Results and Financial Outlook. As of June 30, 2023, Synlogic had cash and cash equivalents of $46.3 million. Revenue for the three months ended June 30, 2023 was $35 thousand compared to $152 thousand for the corresponding period in 2022. Revenue in both periods was primarily associated with the ongoing research ... Sep 28, 2023 · Synlogic enacted this reverse stock split to boost the price of its shares and avoid delisting. The company’s stock previously closed out trading at just 28 cents. That’s below the $1 minimum ... Upon closing, Synlogic security holders are expected to own approximately 83.18% of the outstanding shares of MIRN common stock on a fully- diluted basis and security holders of MIRN as of immediately prior to the merger are expected to own approximately 16.82% of the outstanding shares of MIRN common stock.The latest price target for . Synlogic (NASDAQ: SYBX) was reported by Chardan Capital on August 11, 2023.The analyst firm set a price target for $6.00 expecting SYBX to rise to within 12 months (a ...Dec 15, 2022 · Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. Synlogic saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 90,800 shares, a decline of 41.7% from the previous total of 155,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment.

Dec 1, 2023 · Based on short-term price targets offered by three analysts, the average price target for Synlogic, Inc. comes to $21.67. The forecasts range from a low of $6.00 to a high of $35.00. The average ... Jun 30, 2023 · Second Quarter 2023 Financial Results and Financial Outlook. As of June 30, 2023, Synlogic had cash and cash equivalents of $46.3 million. Revenue for the three months ended June 30, 2023 was $35 thousand compared to $152 thousand for the corresponding period in 2022. Revenue in both periods was primarily associated with the ongoing research ... Synlogic ( NASDAQ:SYBX ) First Quarter 2023 Results Key Financial Results Net loss: US$15.6m (flat on 1Q 2022). ... It does not constitute a recommendation to buy or sell any stock, ...Instagram:https://instagram. best day trade stockwhy tesla stock is going upprofessional forex trader course freesandhill investment management Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. does allstate offer pet insurancehome loan rates mn ١٣‏/٠٦‏/٢٠١٩ ... ... shares of Synlogic common stock, both at a price of $9.00 per share. Gross proceeds to Synlogic are approximately $80 million. The ... pkst stock Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.The value each SYBX share was expected to gain vs. the value that each SYBX share actually gained.. Synlogic (SYBX) reported Q3 2023 earnings per share (EPS) of-$2.57, missing estimates of -$2.18 by 17.89%.In the same quarter last year, Synlogic's earnings per share (EPS) was-$3.73.Synlogic is expected to release next earnings on …